Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA-binding protein with serine-rich domain 1 (RNPS1) is a nucleocytoplasmic shuttling protein encoded by the RNPS1 gene in humans. RNPS1 is a core component of the exon junction complex (EJC), which is recruited to newly spliced mRNA. It participates in mRNA nuclear export, mRNA surveillance, and especially in nonsense-mediated mRNA decay (NMD), a quality control mechanism targeting mRNAs with premature stop codons for degradation. RNPS1 is also involved in both constitutive and substrate-dependent alternative splicing, often modulating the expression of apoptotic genes such as Bcl-X. It forms part of larger multiprotein complexes (e.g., ASAP and PSAP) that transiently associate with the EJC during pre- and post-splicing mRNA processing. RNPS1 is not typically considered a classical therapeutic target such as a receptor or enzyme, but its dysregulation is associated with cancer and certain neurodegenerative and skeletal diseases[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA-binding protein with serine-rich domain 1 (RNPS1).